Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAES-LTFU: Long-term Follow-up of Imlifidase Prior to Kidney Transplantation
NCT05937750Phase 3Active, not recruiting
- Sponsor
- Hansa Biopharma
- Start
- Jul 2023
- Primary completion
- Apr 2030
- Modality
- Therapeutic Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of imlifidase in kidney transplant rejection, sponsored by Hansa Biopharma. Started Jul 2023; status: active, not recruiting.
02
Drugs
imlifidase
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05937750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937750.